Immunocore to present at UBS and Jefferies investor conferences in November 2026
Alpha Vantage · Pluang · · AI-summarised by FinFlash
Immunocore Holdings plc, a biotechnology company, announced its participation in the UBS Global Biopharma Conference and Jefferies London Global Healthcare Conference in November 2026. The company will provide updates on its pipeline and progress, including its approved oncology drug KIMMTRAK. These presentations will be webcast live to offer investors insights into Immunocore's developments and future strategies.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.